Prokinetic drugs are being used with increasing frequency in the treatment of functional gastrointestinal disorders including functional dyspepsia (FD) and constipation-predominant Irritable Bowel Syndrome (IBS-C). Mosapride is a gastro-prokinetic agent that acts as a selective 5-HT4 agonist thereby accelerating gastric emptying. It has been used for the treatment of irritable bowel syndrome (IBS), functional dyspepsia (FD), and gastroesophageal reflux (GERD). Mosapride shares physiologic effects with previous 5-HT4 agonists, cisapride and tegaserod, but with a safer cardiac profile.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I am happy to provide an endorsement for Journal of Experimental Neuroscience because the editor provided a great deal of flexibility in providing an opportunity to publish. I must also commend the helpful staff at Libertas who have facilitated the publishing process.